Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Javier Cortés, Véronique Dieras, Jungsil Ro, Jérôme Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espié, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu
Institutions: Hospital Universitario Ramón y Cajal, Vall d'Hebron Institute of Oncology, Institut Curie, National Cancer Center, Centre Antoine Lacassagne, Centre Léon Bérard, University of California, Los Angeles, Centre Hospitalier Universitaire de Lille, Centre Oscar Lambret, Hôpital Saint-Louis, Asan Medical Center, University of Ulsan, University Hospital Heidelberg, National Center for Tumor Diseases, Severance Hospital, Centre Jean Perrin, Tampere University Hospital, University of Tampere, Sansum Medical Clinic, University of Modena and Reggio Emilia, Hospital Universitario 12 De Octubre, University of Helsinki, Helsinki University Hospital, Boehringer Ingelheim (France)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Boehringer Ingelheim
OpenAlex ID: W2175378170